Atopic dermatitis (AD) is now a global health problem and has been attracting extensive
attention from both academic and public society in China. This review aimed to present the …

In atopic dermatitis (AD), recent research advances have portrayed a complex disease
profile based on different subtypes/phenotypes and underlying molecular mechanisms …

Background Atopic dermatitis (AD) is a chronic inflammatory cutaneous disease that affects
30.48% of young children; thus, there is a need for epidemiological studies in community …

Background: Atopic dermatitis (AD) is an inflammatory skin disease of multiple phenotypes
and endotypes, and is highly prevalent in children. Many people of all ages, including active …

Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by
blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 …

Atopic dermatitis (AD) is a common chronic, multisystem inflammatory skin disease in
pediatric patients. There has been an increase in the incidence of AD in the pediatric …

Introduction Atopic dermatitis (AD) exhibits difference in immune polarization between
Caucasians and Asian races due to which an evaluation of the efficacy and safety of …

The skin commensal Staphylococcus epidermidis exhibits a protective role in skin
inflammation; however, the exact functions of S. epidermidis and their mechanisms in atopic …

ABSTRACT TRPV3 is a temperature-sensitive calcium-permeable channel. In previous
studies, we noticed prominent TUNEL-positive keratinocytes in patients with Olmsted …

Background Stapokibart/CM310, a humanized monoclonal antibody targeting the interleukin-
4 receptor α chain, has shown promising treatment benefits in patients with moderate-to …